Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. 

At Kronos Bio, we have two molecules that have emerged from our product engine. KB-0742, our CDK9 inhibitor, is being evaluated in a phase 1/2 clinical trial as a treatment for patients with MYC-dependent tumors such as triple negative breast cancer, non-small cell lung cancer and ovarian cancer, as well as patients with transcription factor fusion-driven cancers and other transcriptionally addicted cancers including chordomas, sarcomas and small cell lung cancer. Our new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription program that drives multiple myeloma.

Additionally, Kronos Bio began a discovery collaboration with Genentech in January 2023. Our companies are working together to advance novel therapies against transcriptional targets in oncology.

For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW. 

Woodline Partners

BlackRock

Commodore Capital

Nextech Invest

Surveyor Capital

T. Rowe Price

Vida Ventures

Fidelity

Fidelity Management and Research Company

Google Ventures

Invus

Kronos Bio

This week our team enjoyed a lunch and learn with Martin Larke, Senior Scientist, Computational Biology, about how we are using machine learning to understand cellular response to stress. This is an important topic in oncology research and one that is central to Kronos Bios’ development of therapeutics that target deregulated transcription. Thanks Martin for such an engaging session!

Members of the Kronos Bio team were busy this week at the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. We shared our progress developing therapeutics that target deregulated transcription with investors and potential partners, including the latest on our first internally discovered molecule, KB-0742, a CDK9 inhibitor, as well as our new development candidate, KB-9558, a p300 KAT inhibitor. Thanks to everyone who met with us at #JPM. We appreciate your time, interest, and insights. 2024 is off to a good start!

- with Norbert Bischofberger, Barbara Kosacz, Jorge DiMartino, Christopher Dinsmore, Charles Lin, Sarah Connors, and Margaux Bennett

Wishing you and your family health, happiness and success in 2024!

Today, Kronos Bio announced updates to our pipeline including a new development candidate, KB-9558, which targets the KAT domain of p300, for use in multiple myeloma. To learn more, check out our press release here: https://lnkd.in/eNzhCYTK 

Richard Cutler, Ph.D., Vice President of Clinical Science at Kronos Bio, enjoyed presenting a Trial in Progress poster on our CDK9 inhibitor KB-0742 in triple negative breast cancer at the San Antonio Breast Cancer Symposium (SABCS). With more than 10,000 clinicians and scientists from all over the world, SABCS represents a great opportunity for scientific exchange on the latest in breast cancer research. Thank you Rich for representing Kronos Bio!

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue						6.29M -
cost of revenue						4.92M -
gross profit						1.37M -
selling and marketing expenses						-3.78M -
general and administrative expenses	1.61M -	3.37M 109.06%	14.79M 338.99%	38.49M 160.21%	43.40M 12.74%	41.74M 3.83%
selling general and administrative expenses	1.61M -	3.37M 109.06%	14.79M 338.99%	38.49M 160.21%	43.40M 12.74%	37.96M 12.54%
research and development expenses	5.03M -	13.45M 167.16%	43.25M 221.66%	112.90M 161.05%	93.72M 17.00%	82.34M 12.13%
other expenses			-27.41M -
cost and expenses	6.64M -	16.82M 153.06%	58.04M 245.17%	151.40M 160.83%	137.12M 9.43%	125.22M 8.68%
operating expenses	6.64M -	16.82M 153.06%	58.04M 245.17%	151.40M 160.83%	137.12M 9.43%	120.30M 12.26%
interest expense	76K -		3.89M -		-2.27M -	9.16M 504.10%
ebitda	-6.55M -	-16.46M 151.14%	-84.55M 413.69%	-151.08M 78.68%	-137.12M 9.24%	-114.01M 16.85%
operating income	-6.64M -	-16.82M 153.06%	-58.04M 245.17%	-151.40M 160.83%	-137.12M 9.43%	-118.93M 13.26%
depreciation and amortization	91K -	356K 291.21%	-26.51M 7,546.63%	320K 101.21%	2.27M 608.13%	4.92M 116.95%
total other income expenses net	-76K -	699K 1,019.74%	-30.40M 4,449.07%	320K 101.05%	3.91M 1,122.19%	6.26M 59.98%
income before tax	-6.72M -	-16.12M 139.80%	-88.44M 448.76%	-151.08M 70.82%	-133.20M 11.83%	-112.67M 15.41%
income tax expense		-699K -	-24.36M 3,384.55%	-1.98M 91.88%	-3.91M 97.82%
net income	-6.72M -	-15.42M 129.40%	-64.09M 315.66%	-149.10M 132.65%	-129.29M 13.28%	-112.67M 12.85%
weighted average shs out	28.45M -	28.45M 0%	16.28M 42.79%	54.75M 236.38%	56.20M 2.64%	57.74M 2.74%
weighted average shs out dil	28.45M -	28.45M 0%	16.28M 42.79%	54.75M 236.38%	56.20M 2.64%	57.74M 2.74%
eps	-0.24 -	-0.54 125.00%	-3.94 629.63%	-2.72 30.96%	-2.30 15.44%	-1.95 15.22%
epsdiluted	-0.24 -	-0.54 125.00%	-3.94 629.63%	-2.72 30.96%	-2.30 15.44%	-1.95 15.22%

COM:KRONOSBIO

Kronos Bio, Inc.

Last Close

0.86

21/11 19:29

Market Cap

75.72M

Beta: -

Volume Today

169.84K

Avg: -

Preview